Evidence map›Paper›PMID 24029121›Full record

GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2013

Acute myeloid leukemia, version 2.2013.

Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, Jessica K Altman, Frederick R Appelbaum, Daniel A Arber, Eyal Attar, Uma Borate, Steven E Coutre, Lloyd E Damon and 15 more

Registry-linked trialAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02193880 (Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant), which is not on this map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02193880 nacompletednot on this mapstarted 2014, after this paper: background citation

Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)

TypeinterventionalSponsorAyman SaadRan2014 to 2018Enrolled7ConditionsHematologic Neoplasms, Graft-Versus-Host DiseaseArmsAlpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
3 · Its place in the literature

Who cites it

75 citing papers in PubMed.

  1. Trial
  2. Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Margaret R O'DonnellFrom 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 5Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 6Stanford Cancer Institute; 7Massachusetts General Hospital Cancer Center; 8University of Alabama at Birmingham Comprehensive Cancer Center; 9UCSF Helen Diller Family Comprehensive Cancer Center; 10Moffitt Cancer Center; 11UNMC Eppley Cancer Center at The Nebraska Medical Center; 12The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 13St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 14Fox Chase Cancer Center; 15Duke Cancer Institute; 16The University of Texas MD Anderson Cancer Center; 17Huntsman Cancer Institute at the University of Utah; 18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 19Dana-Farber Cancer Institute; 20Vanderbilt-Ingram Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.
Martin S Tallman
Camille N Abboud
Jessica K Altman
Frederick R Appelbaum
Daniel A Arber
Eyal Attar
Uma Borate
Steven E Coutre
Lloyd E Damon
Jeffrey Lancet
Lori J Maness
Guido Marcucci
Michael G Martin
Michael M Millenson
Joseph O Moore
Farhad Ravandi
Paul J Shami
B Douglas Smith
Richard M Stone
Stephen A Strickland
Eunice S Wang
Kristina M Gregory
Maoko Naganuma
National Comprehensive Cancer Network

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHumansLeukemia, Myeloid, AcuteLeukemia, Promyelocytic, Acute

Identifiers

PMID24029121
PMCPMC4161234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.